Inivata, N-of-One Partner
News Nov 04, 2016
Inivata and N-of-One Inc have announced a new partnership to support analysis of patient cases for Inivata’s InVision® liquid biopsy product line. This partnership will enable the delivery of clear, easy to interpret patient reports, providing physicians with a wealth of genomic information at their fingertips. Inivata’s revolutionary approach to ctDNA analysis delivers industry leading sensitivity across a broad panel of clinically relevant genomic alterations.
The Next-Generation Sequencing-based method utilizes eTAm-Seq™, a proprietary amplification process, prior to sequencing and advanced analytical methods that enables the separation of true cancer mutations from background noise. The collaboration with N-of-One will provide each physician with an individualized liquid biopsy report based on their cancer patient’s unique genomic signature. N-of-One’s oncologists and Ph.D. scientists will also provide the analysis needed to assess current treatments, analyze potential novel mutations and allow the oncologists to make more informed decisions for treatment strategies.
Inivata has also recently announced the launch of a large-scale, prospective clinical validation study in non-small cell lung cancer and additional studies are currently underway. “N-of-One’s experience in curating complex genomic information and translating this data into clinically relevant results on tens of thousands of patients has enabled them to develop a market-leading database and unparalleled expertise. We are excited to access their capabilities to ensure we provide physicians with the most actionable information in our easy to interpret report,” said Michael Stocum, CEO of Inivata.
N-of-One will support Inivata’s liquid biopsy assay by providing oncologists and pathologists with the most relevant oncology treatment options through the analysis of each patient’s unique molecular profile. The N-of-One solution will integrate the interpretation of multiple molecular tests on a patient to provide a comprehensive view of the cancer and, leveraging N-of-One’s proprietary database, will identify individualized treatment options, including clinical trials for consideration by the oncologist.
N-of-One’s experience in oncology, and specifically liquid biopsies, makes them uniquely capable of interpreting the Inivata liquid biopsy test. “We are pleased to partner with Inivata in support of the launch of their revolutionary ctDNA platform capabilities,” said Chris Cournoyer, CEO of N-of-One. “Pairing Inivata’s highly sensitive analysis of actionable mutations with N-of-One’s ability to analyze the data of novel mutations has the potential to help guide more personalized treatment decisions for patients prior to and throughout the cancer care continuum.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE